Abdel-Rahman O - Search Results

1

Eltobgy M, Oweira H, Petrausch U, Helbling D, Schmidt J, Mehrabi A, Schöb O, Giryes A, Decker M, Abdel-Rahman O. Eltobgy M, et al. Expert Rev Neurother. 2017 Jul;17(7):725-736. doi: 10.1080/14737175.2017.1336088. Epub 2017 May 31. Expert Rev Neurother. 2017. PMID: 28548892

2

Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Expert Rev Anticancer Ther. 2014 Jun;14(6):751-60. doi: 10.1586/14737140.2014.894465. Epub 2014 Mar 26. Expert Rev Anticancer Ther. 2014. PMID: 24666215 Review.

3

Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Expert Rev Anticancer Ther. 2014 Sep;14(9):1063-73. doi: 10.1586/14737140.2014.929501. Epub 2014 Jun 13. Expert Rev Anticancer Ther. 2014. PMID: 24927771 Review.

4

Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Expert Opin Drug Saf. 2014 Aug;13(8):999-1008. doi: 10.1517/14740338.2014.921679. Epub 2014 Jun 14. Expert Opin Drug Saf. 2014. PMID: 24930544 Review.

5

Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Crit Rev Oncol Hematol. 2014 Dec;92(3):194-207. doi: 10.1016/j.critrevonc.2014.06.003. Epub 2014 Jul 1. Crit Rev Oncol Hematol. 2014. PMID: 25028151 Review.

6

Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Expert Rev Anticancer Ther. 2014 Oct;14(10):1229-42. doi: 10.1586/14737140.2014.948860. Epub 2014 Aug 14. Expert Rev Anticancer Ther. 2014. PMID: 25119858

7

Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Crit Rev Oncol Hematol. 2015 Feb;93(2):127-35. doi: 10.1016/j.critrevonc.2014.07.005. Epub 2014 Aug 12. Crit Rev Oncol Hematol. 2015. PMID: 25139841 Review.

8

Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Expert Rev Anticancer Ther. 2014 Dec;14(12):1529-36. doi: 10.1586/14737140.2014.953936. Epub 2014 Aug 27. Expert Rev Anticancer Ther. 2014. PMID: 25159115 Review.

9

Second line systemic therapy options for advanced hepatocellular carcinoma; a systematic review.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Expert Rev Anticancer Ther. 2015 Feb;15(2):165-82. doi: 10.1586/14737140.2015.978295. Epub 2014 Nov 3. Expert Rev Anticancer Ther. 2015. PMID: 25363192 Review.

10

Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Future Oncol. 2014 Oct;10(12):1981-92. doi: 10.2217/fon.14.42. Future Oncol. 2014. PMID: 25386814 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

347 results

Search Page

Filters